Another paper by Ba Yi, vice president and professor of Tianjin Cancer Hospital, as one of the communication authors, was withdrawn. This is the fifth article in six months.
According to public information, Bayi is the daughter of Ba Denian, an academician of China Academy of Engineering and an immunologist.
On June 24th, 2022,165438+1October 24th, the international academic journal International Journal of Cancer published a retraction statement, saying that Ba Yi, vice president of Tianjin Cancer Hospital, and Ying Guoguang, deputy director of Tianjin Cancer Research Institute were the same correspondent's papers.
According to the above explanation about the retraction, the retraction of the paper was approved by Professor ChristophPlass, the editor-in-chief of the journal, the signed author and the publishing house. "This withdrawal was completed after a detailed internal analysis of the published photos. The results show that there are improper image copying and manipulation in figures 2a, 5c, 5k, 5l and 6c. The author was asked to provide raw data. But in this batch of data, the problems of figures 5k and 5l also appear. Figs. 2a and 5c were reused in subsequent publications with different scientific backgrounds. "
In addition, the SGC-790 1 cell line in the paper also raised questions. This cell line was originally considered as a gastric cancer cell line, but at the same time it was a derivative cell line of HeLa cell line. The authors re-identified the cell line and claimed that the cell line they used in the above study was HGC-27 gastric cancer cell line instead of SGC-790 1. Nevertheless, it is still uncertain which cells were used in the experiment four years ago. "
The title of the above paper is "Exocrine circular RNA from gastric tumors promotes the browning of white fat by targeting the miR- 133/PRDM 16 pathway".
The signed authors of the paper include. Zhang Haiyang, Zhu Lei, Bai Ming, Liu Ying, Yangzi, Deng Ting, Haiyang, Sun Wu, Wang Xinyi, Ke Ganzhu, Qian Fan, Li Jialu, Guo Guangying, September 18th.
Notes on Withdrawal of Articles Published Online by International Journal of Cancer on June 24th, 2022 +065438+
The papers involved were published on 20 18 1 1.9. Correspondents are Ying Guoguang and Bayi. Both of them were signed by Tianjin Medical University Cancer Hospital, National Cancer Clinical Research Center, Tianjin Cancer Clinical Research Center and Tianjin Key Laboratory of Cancer Prevention and Treatment.
In addition, in the first half of 2022, four other papers written by Ying Guoguang as a correspondent of * * * have been withdrawn one after another because of abnormal data or suspected reuse of pictures.
Official website, Tianjin Cancer Hospital, said that this hospital is the birthplace of oncology in China, a large-scale third-class first-class cancer specialist hospital integrating medicine, teaching, research, prevention and health, the first batch of national cancer clinical medical research center, and the Cancer Clinical College of Tianjin Medical University. The oncology discipline in our hospital is a national key discipline, and the oncology discipline group entered the ranks of the national "double first-class" discipline construction on 20 17; At present, there are 4 provincial key laboratories, 2 innovation teams of the Ministry of Education,/kloc-0 innovation teams in key fields of the Ministry of Science and Technology, national clinical drug testing institutions and clinical pharmacist training pilot bases of the Ministry of Health. China Cancer Clinic sponsored by our hospital is a national first-class core publication. CancerMedical, an English periodical, took the lead in developing MDT comprehensive diagnosis and treatment in Tianjin, which promoted the standardization process of digestive system tumor treatment in Tianjin and promoted the individualized treatment model. Over the years, tens of thousands of patients with digestive system tumors have been diagnosed and treated, the survival rate of patients has increased by nearly 10%, the quality of life of patients has been improved, and rich treatment experience has been accumulated, and the overall medical level is in the leading position in China.
According to the above information, Bayi is also the chairman of the Cancer Support and Treatment Professional Committee of China Anti-Cancer Association, the vice chairman of the Cancer Clinical Chemotherapy Professional Committee, the vice chairman of the Cancer Clinical Research Professional Committee, the vice chairman of the National Oncologist Regular Evaluation Editorial Committee, the vice chairman of the Cancer Branch of the Chinese Medical Doctor Association, the expert of colorectal cancer group of the Department of Medical Administration of the Ministry of Health, the member of the oncology degree evaluation sub-committee of Tianjin Medical University, and the expert of medical accident technical appraisal of Tianjin Medical Association.
An article published in China Book Review, the official account of WeChat, on June 25th, 2022 mentioned that "At present, Vice President Bayi of Tianjin Medical University Cancer Hospital is the daughter of Academician Ba Denian, but in the oral work On Earth: Personal Record of Female Oncologists, it seems that the female oncologists are the first to show a sense of confrontation with their fathers". She said: "Born in such a family, we will get less recognition than others. Even if we make the same efforts and eat on our own, it is easy to be labeled as' just because you have such a father'. "
Official website of Tianjin Cancer Hospital and Cancer Institute shows that Professor Ying Guoguang, supervisor of doctoral students, deputy director of Tianjin Cancer Institute, director of tumor cell biology laboratory, director of Tianjin Key Laboratory of Cancer Prevention and Treatment, and chairman of innovation strategic alliance of Tianjin Key Laboratory of medical and health fields; Participated in the pilot research and industrial development of genetic engineering products under the National 863 Program, and won the first and second prizes of national scientific and technological progress; He has published more than 40 academic papers in international professional magazines such as Journal of Immunology and Journal of Immunology.
Ying Guoguang also served as a member of Medical Cell Biology Branch of Chinese Medical Association, Cancer Etiology Branch of China Anti-Cancer Association, Cancer Metastasis Branch of China Anti-Cancer Association, deputy editor-in-chief of China Cancer Clinic, and member of the editorial board of Clinical Cancer Research.
Attached are four other papers of the author whose correspondence was withdrawn in August 1st, 2022:
1.On March 8, 2022, the international academic journal Molecular Therapy-Nucleic Acid published a retraction statement online. On October 29th, 2020/kloc-0, the research paper entitled "Exosimir-155 derived from gastrin gene promoter by targeting c-MYB/vegfaxisofenendothelial cells" published on the Internet by Professor Ba Yi and Professor Ying Guoguang from Tianjin Cancer Hospital was withdrawn.
Papers withdrawn from the international academic journal Molecular Therapy-Nucleic Acid on March 8, 2022.
According to the retraction statement, the editorial department of the journal withdrew the above papers. After investigating the questions raised by readers about image copying in this paper, the evidence of the problem of copying images in the same or disguised way in Figures 3A, 5D, 6E and 7A is confirmed. This practice of reusing data without proper attribution is a serious abuse of the scientific publishing system.
The authors who participated in the thesis are: Deng Ting, Zhang Haiyang, Ouyang Hai, Hui Yawang, Bai Ming, Sun Wu, Wang Xinyi, Yi Lansi, Tao Ning, Zhang Le, Li Hongli, Shao Huage, Liu Rui, Lin Dan, Shuangli, Guo Guangying and Yiba.
Links to Notes for Withdrawal: Molecular-Therapy-Family/Nucleic Acid/Full Text/S2162-253100042-7? _ returnurl =% 2fretrieval% 2fpii% 2fs2162253122000427% 3fshowall% 3dtrue # Related articles
2. On May 10, 2022, the international academic journal Molecular Therapy-Oncolytic Virus published a retraction statement on the Internet, saying that on May1910, Professor Ba Yi of Tianjin Cancer Hospital and Ying Guoguang, as the co-author of * * *, published an article entitled "Exosomes Carrying MicroRNA-/KL"
According to the retraction statement, the editorial department of the journal withdrew the above papers. After investigating the questions raised by readers about image copying in this paper, the evidence of the problem of copying images in the same or disguised way in figures 1A, 1E, 3A, 3C, 4C and 4G is confirmed. This practice of reusing data without proper attribution is a serious abuse of the scientific publishing system.
The authors who participated in the thesis are: Zheng Yangzhou, Zhang Haiyang, Deng Ting, Tao Ning, Liu Rui, Dong Yingliu, Bai Ming, Guo Guangying and Bai Yi.
Explanatory link for retraction: Molecular-Therapy-Family/Oncology/Full Text/S2372-770500065-1# Related articles.
3. On May 23, 2022, the international academic journal Molecular Therapy published a retraction statement on the Internet, saying, On August 3rd, 2065438, the research paper entitled "Mir-130A Activated Sangiogenesis Sisingastriccancerby Targeting C-Mybinvascuralendolealcells" published by Professor Ba Yi and Professor Ying Guoguang from Tianjin Cancer Hospital as the same correspondent was withdrawn.
According to the retraction statement, the editorial department of the journal withdrew the above papers. After investigating the questions raised by readers about image copying in this paper, the evidence of the problem of copying images in the same or disguised way in Figures 4A, 4G and S 1C is confirmed. This practice of reusing data without proper attribution is a serious abuse of the scientific publishing system. The signed author does not agree to withdraw the paper.
The authors who participated in the thesis are: Ouyang Hai, Zhang Haiyang, Shao Huage, Tao Ning, Bai Ming, Li Jialu, Li Shuang, Sun Wu, Deng Ting, Zhang Le, Guo Guangying and Bayi.
Notes on the withdrawal of the draft: molecular therapy-family/molecular therapy/full text/s1525-001600180-0.
4. On May 23, 2022, the international academic journal Molecular Therapy published a retraction statement on the Internet, saying that Professor Ba Yi and Professor Ying Guoguang of Tianjin Cancer Hospital published on the Internet on July 25, 20 19, entitled "Mir- 135 b expressed endothelial cells by gastric tumor exosomes inhibitory factor foxo 1.
According to the retraction statement, the editorial department of the journal withdrew the above papers. After investigating the questions raised by readers about image duplication in this paper, the evidence of image duplication in Figure 7B is confirmed. The evidence of the image is reproduced in the same or changed way in fig. 7B. This practice of reusing data without proper attribution is a serious abuse of the scientific publishing system. The signed author does not agree to withdraw the paper.
The authors who participated in the thesis are Bai Ming, Li Jialu, Zhang Haiyang, Zhang Haiyang, Zhou Zhengyang, Deng Ting, Ke Ganzhu, Tao Ning, Qian Fan, Guo Guangying and Bai Yi.
Explanatory link for draft retraction: molecular-therapy-family/molecular-therapy/fulltext/s1525-001600181-2.